Data and clinical trials powerhouse unifies brand under new banner.

In May 2016, drug trial manager Quintiles and data-mining IMS Health Holdings announced their merger amidst a certain amount of skepticism from the investment community. A year later, QuintilesIMS Holdings announced its new name: IQVIA, which the company said names its brand dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients.

Effective November 6, IQVIA will offer equity shares for trade on the New York Stock Exchange under the ticker symbol “IQV” as well as maintaining its listing as QuintilesIMS per stock exchange requirements.

IQVIA said that at the center of its customer solutions is IQVIA CORE,TM which enables it to provide individualized solutions for clients seeking to leverage the curated healthcare information source. According to IQVIA, its database provides extensive industry knowledge across diseases, geographies and scientific methods. Further, said the company, their offering helps provide customers’ new approaches to human data science, including framing a more predictable clinical development environment and better integration of the process from “molecule to market.”

IQVIA Chairman and CEO Ari Bousbib offered his appraisal of the new brand. “Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward. Our clients have been instrumental in our becoming IQVIA.”

IMS Health and Quintiles came together, said Bousbib, because clients were asking for more effective ways to bring pharma innovation to patients and capture the improvements the industry has been pursuing for years. “Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings. Our vision is to outpace the inevitable progress of change across the life sciences and accelerate our ability to empower healthcare decision makers to meet the future head on.”